Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors

Inclusion Criteria: * Age greater than or equal to 18 * A pituitary adenoma/carcinoma of any histology ° Patients with unresectable tumors that are radiographically (and/or biochemically) consistent with a pituitary adenoma may be considered for enrollment without pathologic confirmation with approval from the principal investigator. * Progression on imaging following radiotherapy ° Patients with pituitary carcinomas in whom there is not felt to be a palliative benefit to treatment with radiotherapy are eligible for enrollment without prior radiotherapy. * Measurable disease by RANO criteria * At least 4 weeks have elapsed since the patient last received temozolomide and the patient must have recovered hematologically from other chemotherapeutics * Karnofsky Performance Status (KPS) greater than or equal to 70 * Screening laboratory values must meet the following criteria: * WBC \>/= 2000/uL * Neutrophils \>/= 1500/uL * Platelets \>/= 100 x 10\^3/uL * Hemoglobin \> 9.0 g/dL * AST/ALT \</=3 x ULN * Total Bilirubin \</= 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin \<3.0 mg/dL) * Serum creatinine \</= 1.5 x ULN or creatinine clearance (CrCl) \>/= 40 mL/min using the Cockcroft-Gault formula * Women of childbearing potential (WOCBP) must use appropriate method(s) or contraception. WOCBP should use an adequate method to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives) after t…